The U.S. Supreme Court has turned aside the bid by pharmaceutical maker Eli Lilly to not only toss out a $183 million judgment against the company, but also put a dent in a system the company says unconstitutionally permits "private bounty hunters" to use questionable legal claims to extract big paydays in the name of the government.